drugset
Drugs / MT-4561
last change Jun 2025 re-read 3 minutes ago

MT-4561

Developed for
biliary tract cancer · breast cancer · cervical cancer · endometrial cancer · esophageal cancer · gastric cancer · head and neck squamous cell carcinoma · neuroendocrine carcinoma
+7 more · non-small cell lung carcinoma · nut midline carcinoma · ovarian cancer · pancreatic ductal adenocarcinoma · prostate cancer · soft tissue sarcoma · urothelial carcinoma
Investigated by
Tanabe Pharma America, Inc.

Trials 1

today NCT06943521 · Ph 1/2
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06943521 Apr 2025 → Aug 2028 expected biliary tract cancer, breast cancer, cervical cancer, endometrial cancer +11 Tanabe Pharma America, Inc. Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2025-06-13 Tanabe Pharma Corporation Initiation of Phase 1/2 clinical trial of MT-4561 for Advanced Solid Tumors tanabe-pharma.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MT-4561 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06943521 ↗
Route Intravenous “Intravenous (IV) infusion of MT-4561 once every week in 28-day cycle” NCT06943521 ↗